david-inf/am-nlp-abstrct · Datasets at Hugging Face

text stringlengths 21 669	label int64 0 2
Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.	1
TMMC and T5-FU appeared to have similar efficacy in lowering IOP.	1
Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.	1
Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.	0
Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	2
At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).	0
The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (5·6 months, 95% CI 5·0-6·2 vs 4·9 months, 4·5-5·4; hazard ratio 1·3, 95% CI 1·1-1·6, p=0·014).	0
The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.	1
in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	1
Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	0
HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	1
Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).	0
a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).	0
A positive longitudinal impact of the intervention on symptom discussion was observed,	0
No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking.	0
The survival was similar to that of transthoracic approach.	1
The timing of RT has minimal impact on the function of STS patients in the first year after surgery	1
Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.	0
At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	0
This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.	1
no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).	0
At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.	0
Median survival was 8.3 months and 7.9 months,	0
Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.	1
In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.	2
There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.	0
The perioperative and serious postoperative complications ratios were comparable between the groups.	1
Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	0
Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.	1
The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,	0
DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).	0
Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.	0
Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	1
the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).	0
Therefore, we recommend no additional clinical use of TCG in this population.	2
The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.	0
We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.	1
Symptoms and QoL seem not to be significantly affected by GKRS.	1
It has a safe systemic profile with minimum effect on the heart.	1
No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.	0
There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).	0
Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).	0
Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.	0
A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	1
However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.	0
Both groups had a similar favorable long-term safety profile.	1
Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.	0
Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	0
No difference in survival was detected between the groups;	0
The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	0
However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.	0
There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.	0
Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).	0
complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	0
However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	0
These differences were not observed between baseline and T3 and T4 assessments.	0
Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,	1
Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.	1
The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).	0
A second infusion of pamidronate did not decrease resorption further,	0
Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.	0
OS, PFS, QOL, and RR were comparable between arms.	0
Small sample size precludes definitive answers,	1
Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	1
Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;	0
Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.	1
Hypotony was noted in 3 eyes in each group.	0
There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	0
By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	1
Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)	0
Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	0
The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.	1
but few sustained effects.	0
Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	1
Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).	0
All therapies were well tolerated.	1
Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.	0
Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	0
There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.	0
physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	0
further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	1
Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).	0
we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.	1
LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	1
Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.	0
At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.	0
Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	0
Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.	0
These physical changes can negatively affect health-related quality of life.	1
Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.	1
but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	0
the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);	0
Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.	0
Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.	1
patients were more likely to achieve lower target pressures with BTFC than with TTFC.	1
Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.	0
There were no significant intervention by subgroup interactions (P>.10).	0
XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).	0
the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).	0
However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.	1

Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term.

1

TMMC and T5-FU appeared to have similar efficacy in lowering IOP.

1

Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.

1

Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.

0

Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.

2

At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).

0

The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (5·6 months, 95% CI 5·0-6·2 vs 4·9 months, 4·5-5·4; hazard ratio 1·3, 95% CI 1·1-1·6, p=0·014).

0

The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.

1

in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.

1

Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),

0

HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.

1

Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02).

0

a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013).

0

A positive longitudinal impact of the intervention on symptom discussion was observed,

0

No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking.

0

The survival was similar to that of transthoracic approach.

1

The timing of RT has minimal impact on the function of STS patients in the first year after surgery

1

Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.

0

At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.

0

This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context.

1

no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05).

0

At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy.

0

Median survival was 8.3 months and 7.9 months,

0

Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.

1

In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status.

2

There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups.

0

The perioperative and serious postoperative complications ratios were comparable between the groups.

1

Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).

0

Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible.

1

The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,

0

DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).

0

Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively.

0

Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.

1

the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%).

0

Therefore, we recommend no additional clinical use of TCG in this population.

2

The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.

0

We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.

1

Symptoms and QoL seem not to be significantly affected by GKRS.

1

It has a safe systemic profile with minimum effect on the heart.

1

No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.

0

There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).

0

Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).

0

Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.

0

A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.

1

However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities.

0

Both groups had a similar favorable long-term safety profile.

1

Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-β) and in the hepatitis B virus DNA levels were compared between the groups.

0

Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).

0

No difference in survival was detected between the groups;

0

The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.

0

However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.

0

There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.

0

Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).

0

complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.

0

However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).

0

These differences were not observed between baseline and T3 and T4 assessments.

0

Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,

1

Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.

1

The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02).

0

A second infusion of pamidronate did not decrease resorption further,

0

Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA.

0

OS, PFS, QOL, and RR were comparable between arms.

0

Small sample size precludes definitive answers,

1

Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information

1

Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;

0

Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.

1

Hypotony was noted in 3 eyes in each group.

0

There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).

0

By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.

1

Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)

0

Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).

0

The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.

1

but few sustained effects.

0

Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.

1

Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).

0

All therapies were well tolerated.

1

Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.

0

Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.

0

There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.

0

physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)

0

further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,

1

Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).

0

we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.

1

LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.

1

Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.

0

At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.

0

Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).

0

Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.

0

These physical changes can negatively affect health-related quality of life.

1

Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients.

1

but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.

0

the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);

0

Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.

0

Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs.

1

patients were more likely to achieve lower target pressures with BTFC than with TTFC.

1

Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.

0

There were no significant intervention by subgroup interactions (P>.10).

0

XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).

0

the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function).

0

However, its safety should be confirmed by the results of larger randomized trials and meta-analyses.

1